Molecular structure of Procainamide hydrochloride, CAS Number: 614-39-1
Procainamide hydrochloride (CAS 614-39-1)
Alternate Names:
4-Amino-N-[2′-(diethylamino)ethyl]benzamide hydrochloride
Application:
Procainamide hydrochloride is a Na+ channel blocker and Dnmt inhibitor
CAS Number:
614-39-1
Purity:
≥95%
Molecular Weight:
271.8
Molecular Formula:
C13H21N3O•HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Procainamide hydrochloride is the hydrochloride salt preparation of Procainamide, a potent blocker of Na+ channels. This action slows the rate of rise of the action potential, thereby prolonging the recovery period after depolarization. The hydrochloride salt form enhances the solubility of procainamide in water. This form is typically more stable and easier to handle in a biological setting. Procainamide hydrochloride is an inhibitor of DNA methyltransferase (Dnmt). Procainamide is an amide derivative of 4-aminobenzoic acid.
Procainamide hydrochloride (CAS 614-39-1) References
- Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rats. | Zicca, A., et al. 2002. Eur J Pharmacol. 442: 265-72. PMID: 12065080
- Morphological and histochemical evidence of the protective effect of procainamide hydrochloride on tissue damage induced by repeated administration of low doses of cisplatin. | Fenoglio, C., et al. 2005. Anticancer Res. 25: 4123-8. PMID: 16309206
- Stability of amrinone and digoxin, procainamide hydrochloride, propranolol hydrochloride, sodium bicarbonate, potassium chloride, or verapamil hydrochloride in intravenous admixtures. | Riley, CM. and Junkin, P. 1991. Am J Hosp Pharm. 48: 1245-52. PMID: 1650135
- Study of feasibility of the treatment with procainamide hydrochloride and cisplatin in pregnant mice. | Ognio, E., et al. 2006. Chem Biol Interact. 164: 232-40. PMID: 17084828
- Fundamentals of ionic conductivity relaxation gained from study of procaine hydrochloride and procainamide hydrochloride at ambient and elevated pressure. | Wojnarowska, Z., et al. 2012. J Chem Phys. 136: 164507. PMID: 22559496
- Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride. | Schaaf, LJ., et al. 1990. Am J Hosp Pharm. 47: 1567-71. PMID: 2368749
- A receptor for type I antiarrhythmic drugs associated with rat cardiac sodium channels. | Sheldon, RS., et al. 1987. Circ Res. 61: 492-7. PMID: 2443266
- Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide. | Atkinson, AJ., et al. 1988. Angiology. 39: 655-67. PMID: 2457345
- A novel, molecularly imprinted polymer sensor made using an oligomeric methyl silsesquioxane-TiO2 composite sol on a glassy carbon electrode for the detection of procainamide hydrochloride. | Wang, K., et al. 2015. Biosens Bioelectron. 64: 94-101. PMID: 25194802
- Preparation and Antiproliferative Activity of Liposomes Containing a Combination of Cisplatin and Procainamide Hydrochloride. | Viale, M., et al. 2016. Chem Res Toxicol. 29: 1393-5. PMID: 27501273
- Investigation of binding behaviour of procainamide hydrochloride with human serum albumin using synchronous, 3D fluorescence and circular dichroism. | Byadagi, K., et al. 2017. J Pharm Anal. 7: 103-109. PMID: 29404024
- Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. | Riley, CM. 1988. Am J Hosp Pharm. 45: 2079-91. PMID: 3228079
- Stability of procainamide hydrochloride in neutralized 5% dextrose injection. | Raymond, GG., et al. 1988. Am J Hosp Pharm. 45: 2513-7. PMID: 3228104
- Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide. | Roden, DM. and Woosley, RL. 1983. Pharmacol Ther. 23: 179-91. PMID: 6199801
- Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. | Allen, LV. and Erickson, MA. 1996. Am J Health Syst Pharm. 53: 2073-8. PMID: 8870895
Inhibitor of:
2610110G12Rik, 2810422O20Rik, ASMTL, BC014805, C9orf41, Dnmt, Dnmt1, Dnmt2, Dnmt3a, MBD3L3, MBD3L4, MBD6, METTL9, Na+ CP type IIIα, NSUN7, RG9MTD3, SETD4, Slc22a22, SLC22A24, sodium channel type I, sodium channel type III, and Tomt.Activator of:
MBD3L2-5, NAT-2, OCTN2, and RG9MTD2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Procainamide hydrochloride, 10 g | sc-202297 | 10 g | $52.00 |